Engineering antibodies in silico using LENSai™ marks a significant milestone toward the complete de novo design of antibodies, aligning with IPA’s vision to make groundbreaking and safer therapeutics instantly accessible and affordable. Key takeaways: Highly Specific Binding of Novel Antibodies to a Tumor Microenvironment Protein of Previously Unknown Structure – Verified in Laboratory Setting. The […] Read The Rest at :
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.